Cannabis News

InMed Pharmaceuticals entered into a research and development collaboration with ATERA.

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) entered into a research and development collaboration with ATERA.
As quoted in the press release:

Under the terms of the agreement, ATERA will develop 3D human skin models of Epidermolysis Bullosa (‘EB’) to evaluate the in vitro drug efficacy of InMed’s lead compound, INM-750, a proprietary, topical cannabinoid product candidate targeted as a therapy in EB and other potential dermatological and wound-healing applications. ATERA will also investigate the beneficial effects of topically applied INM-750 at ultra-structural cellular and molecular levels on in vitro 3D reconstructed human full thickness (dermis-epidermis) skin models composed of both normal and EB-derived skin cells.
“INM-750 has demonstrated significant potential in pre-clinical models to address symptomatic improvement of EB including accelerated wound healing and a reduction in pain, itch and inflammation.  This project with ATERA is designed to assess the potential of INM-750 to have an impact in disease reversal, further supporting our current data indicating an up-regulation in specific keratins in the skin”, stated Dr. Sazzad Hossain, CSO of InMed. “By utilizing full-thickness skin models derived from EB skin samples, we can better validate INM-750’s target effect and efficacy in vitro ahead of our upcoming clinical trial program.”

Click here to read the full press release.

Source: www.newswire.ca

MARKETS

Markets
TSX20269.97+89.37
TSXV669.57-8.93
DOW34152.01+239.57
S&P 5004305.20+8.06
NASD13102.55-25.50
ASX7105.40+41.10

COMMODITIES

Commodities
Gold1778.69+3.22
Silver20.19+0.06
Copper3.63+0.01
Palladium2161.00+16.00
Platinum938.50+4.50
Oil87.37+0.84
Heating Oil3.47+0.03
Natural Gas9.43+0.10

DOWNLOAD FREE REPORTS

×